7Baggers
 nextcure, inc. (nasdaq:nxtc) sees significant drop in short interest  Defense World Tue, 16 Sep 2025 06:41:56 GMT

NextCure, Inc
(NASDAQ:NXTC) 

NXTC stock logo

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment o...

IPO Price: $15 (May 08, 2019)
Full Time Employees: 69
CEO: Michael S. Richman  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends